Contemplated systems and methods provide for machine learning and identification of regulatory interactions in biological pathways using a probabilistic graphical model, and especially for identification of interaction correlations among the regulatory parameters.
Please help me write a proper abstract based on the patent claims. CLAIM: 1. A learning engine, comprising: an omic input interface configured to receive a plurality of omic datasets; an omic processing module coupled with the interface and configured to: access a pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having a regulatory node that controls activity along the path as a function of a plurality of regulatory parameters; obtain, via the omic input interface, at least one of the omic datasets; infer, based on the at least one omic dataset and the pathway model, a set of interaction correlations among the plurality of regulatory parameters; and update the pathway model based on the interaction correlations. 2. The learning engine of claim 1 wherein the omic datasets comprise whole genome data, partial genome data, or differential sequence objects. 3. The learning engine of any of claims 1-2 further comprising a genomic database or sequencing device coupled to the omic input interface. 4. The learning engine of any one of claims 1-3 wherein the pathway elements comprise at least one of a DNA sequence, a RNA sequence, a protein, and a protein function. 5. The learning engine of any one of claims 1-4 wherein the pathway element comprises a DNA sequence and wherein the at least one of the plurality of regulatory parameters is selected from the group consisting of a transcription factor, a transcription activator, a RNA polymerase subunit, a cis-regulatory element, a trans-regulatory element, an acetylated histone, a methylated histone, and a repressor. 6. The learning engine of any one of claims 1-5 wherein the pathway element comprises a RNA sequence and wherein the at least one of the plurality of regulatory parameters is selected from the group consisting of an initiation factor, a translation factor, a RNA binding protein, a ribosomal protein, an siRNA, and a polyA binding protein. 7. The learning engine of any one of claims 1-6 wherein the pathway element comprises a protein and wherein the at least one of the plurality of regulatory parameters is a phosphorylation, an acylation, a proteolytic cleavage, and association with at least a second protein. 8. The learning engine of any one of claims 1-7 wherein the omics processing module is configured to infer the interaction correlation using a probabilistic model. 9. The learning engine of claim 8 wherein the probabilistic model uses a co-dependent regulation model. 10. The learning engine of claim 8 or 9 wherein the probabilistic model uses an independent regulation model. 11. The learning engine of claim 10 wherein the probabilistic model further determines a significance of dependence between the plurality of the regulatory parameters and the activity of the path and/or a significance of conditional dependence between the regulatory parameters given an activity of the path. 12. The learning engine of claim 11 wherein the probabilistic model further determines the sign of interaction for the regulatory parameters. 13. A method of generating a pathway model, comprising: obtaining, via an omic input interface, at least one omic dataset; accessing, via an omic processing module, a pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having a regulatory node that controls activity along the path as a function of a plurality of regulatory parameters; inferring, via the omic processing module, based on the at least one omic dataset and the pathway model, a set of interaction correlations among the plurality of regulatory parameters; and updating the pathway model based on the interaction correlations. 14. The method of claim 13 wherein the omic datasets comprise whole genome data, partial genome data, or differential sequence objects, and wherein the omic datasets are obtained from a genomic database, a BAM server, or a sequencing device. 15. The method of claim 13 or claim 14 wherein the step of inferring is based on a probabilistic model. 16. The method of claim 15 wherein the probabilistic model uses a co-dependent and/or independent regulation model. 17. The method of claim 16 further comprising a step of determining a significance of dependence between the plurality of the regulatory parameters and the activity of the path and/or a significance of conditional dependence between the regulatory parameters given an activity of the path. 18. The method of claim 17 further comprising a step of determining the sign of interaction for the regulatory parameters. 19. A method of identifying sub-type specific interaction correlations for regulatory parameters of a regulatory node in a pathway model, comprising: obtaining, via an omic input interface, at least one omic dataset representative of a sub-type tissue; accessing, via an omic processing module, the pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having the regulatory node that controls activity along the path as a function of the plurality of regulatory parameters; deriving the sub-type interaction correlations, via the omic processing module, from the at least one omic dataset representative of the sub-type tissue by probability analysis of interactions among the plurality of regulatory parameters; and presenting the derived sub-type interaction correlations in the pathway model. 20. The method of claim 19 wherein the sub-type tissue is a drug-resistant tissue, a metastatic tissue, a drug-treated tissue, or a clonal variant of a tissue. 21. The method of claim 19 further comprising a step of validating the derived sub-type interaction correlations using at least one of an in-vitro, in-silico, and in-vivo experiment. 22. A method of classifying an omic dataset representative of a tissue as belonging to a sub-type specific tissue, comprising: obtaining, via an omic input interface, the omic dataset representative of the tissue; deriving, for the omic dataset, a set of interaction correlations among a plurality of regulatory parameters of a regulatory node in a pathway model; matching the derived set of interaction correlations to an a priori known set of interaction correlations that is associated with a known sub-type specific tissue; and using the match to classify that the omic dataset representative of the tissue belongs to the known sub-type specific tissue. 23. The method of claim 22 wherein the step of obtaining comprises generating the omic dataset representative of the tissue from a tissue sample of a tissue with unknown regulatory characteristic. 24. The method of claim 22 or claim 23 wherein the tissue sample is a tumor tissue sample. 25. The method of any one of claims 22-24 wherein the known sub-type specific tissue is a drug-resistant tissue, a metastatic tissue, a drug-treated tissue, or a clonal variant of a tissue. 26. A method of identifying a druggable target in a pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having a regulatory node that controls activity along the path as a function of a plurality of regulatory parameters, the method comprising: obtaining, via an omic input interface, an omic dataset representative of a tissue; deriving, for the omic dataset, a set of interaction correlations among the plurality of regulatory parameters of the regulatory node in the pathway model; identifying a drug as affecting the activity of the path where the drug is predicted to interfere with the interaction correlations. 27. The method of claim 26 wherein the regulatory node affects at least one of transcription, translation, and post-translational modification of a protein. 28. The method of claim 26 wherein the drug is a commercially available drug and has a known mode of action. 29. A method of identifying a target pathway in a pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having a regulatory node that controls activity along the path as a function of a plurality of regulatory parameters, the method comprising: obtaining, via an omic input interface, an omic dataset representative of a tissue; deriving, for the omic dataset, a set of interaction correlations among the plurality of regulatory parameters of the regulatory node in the pathway model; identifying a pathway as the target pathway based on a known effect of a drug on the interaction correlation. 30. The method of claim 29 wherein the known effect is at least one of an inhibitory effect on a kinase, an inhibitory effect on a receptor, and an inhibitory effect on transcription. 31. The method of claim 29 wherein the target pathway is a calcium/calmodulin regulated pathway, a cytokine pathway, a chemokine pathway, a growth factor regulated pathway, a hormone regulated pathway, MAP kinase regulated pathway, a phosphatase regulated pathway, or a Ras regulated pathway. 32. The method of claim 29 further comprising a step of providing a treatment advice based on the identified pathway. 33. A method of in silico simulating a treatment effect of a drug, comprising: obtaining a pathway model having a plurality of pathway elements in which at least two of the elements are coupled to each other via a path having a regulatory node that controls activity along the path as a function of a plurality of regulatory parameters; identifying a drug that is known to affect at least one regulatory parameter; altering in silico, via an omic processing module and based on the known effect of the drug, at least one of the regulatory node, the activity, and at least of the regulatory parameters in the pathway model; and determining a secondary effect of the alteration in the pathway model. 34. The method of claim 33 wherein the secondary effect is in another regulatory node, another activity, and another regulatory parameter in the pathway model.